Artiva Ebit Per Revenue from 2010 to 2024

ARTV Stock   10.40  0.22  2.07%   
Artiva Biotherapeutics, Ebit Per Revenue yearly trend continues to be fairly stable with very little volatility. Ebit Per Revenue will likely drop to -0.96 in 2024. During the period from 2010 to 2024, Artiva Biotherapeutics, Ebit Per Revenue regression line of quarterly data had r-squared of  0.48 and coefficient of variation of (42.33). View All Fundamentals
 
Ebit Per Revenue  
First Reported
2010-12-31
Previous Quarter
(0.92)
Current Value
(0.96)
Quarterly Volatility
9.40669024
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Artiva Biotherapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Artiva Biotherapeutics,'s main balance sheet or income statement drivers, such as Net Interest Income of 2.7 M, Interest Income of 2.7 M or Depreciation And Amortization of 2.4 M, as well as many indicators such as Price To Sales Ratio of 3.18, Dividend Yield of 0.0 or Days Sales Outstanding of 18.2. Artiva financial statements analysis is a perfect complement when working with Artiva Biotherapeutics, Valuation or Volatility modules.
  
Check out the analysis of Artiva Biotherapeutics, Correlation against competitors.

Latest Artiva Biotherapeutics,'s Ebit Per Revenue Growth Pattern

Below is the plot of the Ebit Per Revenue of Artiva Biotherapeutics, Common over the last few years. It is Artiva Biotherapeutics,'s Ebit Per Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Artiva Biotherapeutics,'s overall financial position and show how it may be relating to other accounts over time.
Ebit Per Revenue10 Years Trend
Slightly volatile
   Ebit Per Revenue   
       Timeline  

Artiva Ebit Per Revenue Regression Statistics

Arithmetic Mean(22.22)
Coefficient Of Variation(42.33)
Mean Deviation7.02
Median(26.61)
Standard Deviation9.41
Sample Variance88.49
Range25.6936
R-Value0.69
Mean Square Error49.99
R-Squared0.48
Significance0
Slope1.45
Total Sum of Squares1,239

Artiva Ebit Per Revenue History

2024 -0.96
2023 -0.92
2022 -12.13

About Artiva Biotherapeutics, Financial Statements

Artiva Biotherapeutics, investors use historical fundamental indicators, such as Artiva Biotherapeutics,'s Ebit Per Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Artiva Biotherapeutics,. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Ebit Per Revenue(0.92)(0.96)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Artiva Stock Analysis

When running Artiva Biotherapeutics,'s price analysis, check to measure Artiva Biotherapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Artiva Biotherapeutics, is operating at the current time. Most of Artiva Biotherapeutics,'s value examination focuses on studying past and present price action to predict the probability of Artiva Biotherapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Artiva Biotherapeutics,'s price. Additionally, you may evaluate how the addition of Artiva Biotherapeutics, to your portfolios can decrease your overall portfolio volatility.